CEA cell adhesion molecule pseudogene 11Genealiases: CEACAM32P · CGM18
Q-omics provides the consensus-scored CEACAMP11 profile across patient tissues and cancer cell-line models. CEACAMP11 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, CEACAMP11 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, CEACAMP11 RNA expression shows 10,219 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THYM, HNSC, and GBM as cancer lineages where CEACAMP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAMP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAMP11 survival associations across molecular data types. CEACAMP11 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAMP11 RNA expression–survival associations across cancer types. High CEACAMP11 expression shows unfavorable associations in THYM, LUAD, COAD, LUSC, PCPG and STAD. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for CEACAMP11 RNA expression.
This table summarizes CEACAMP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CEACAMP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAMP11 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUSC, LIHC, KICH and THCA. The HNSC box plot shows higher CEACAMP11 RNA expression in tumor versus normal tissue (log2 FC = +0.061, t-test p = .002).
This table shows molecular features associated with CEACAMP11 in patient tissues and cancer cell lines. In patient samples, CEACAMP11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
